Home›Breast Cancer›Phase III ASCENT Study of Metastatic TNBC Halted Due to Compelling Efficacy

Phase III ASCENT Study of Metastatic TNBC Halted Due to Compelling Efficacy

January 4, 2022

276

[ad_1]

The decision to halt the study was based on the unanimous recommendation by an independent data safety monitoring committee during its routine review of the ASCENT study.

[ad_2]

Fitcoachion

Problem solver. Creator. Thinker. Web nerd. Food enthusiast. Pop culture junkie. Snowboarder, dreamer, hiphop head, hand letterer and growthhacker. Producing at the crossroads of modernism and programing to express ideas through design. I am 20 years old.